Effects of cardiotrophin-1 on hemodynamics and cardiomyocyte apoptosis in rats with acute myocardial infarction

  • Yin Ruixing
    Department of Cardiology, Institute of Cardiovascular Diseases, Guangxi Medical University
  • Yang Dezhai
    Department of Cardiology, Institute of Cardiovascular Diseases, Guangxi Medical University
  • Li Jiaquan
    Department of Cardiology, Institute of Cardiovascular Diseases, Guangxi Medical University

書誌事項

公開日
2004
資源種別
journal article
DOI
  • 10.2152/jmi.51.29
公開者
国立大学法人 徳島大学医学部

この論文をさがす

説明

The effects of cardiotrophin-1 on hemodynamics, cardiac function, cardiomyocyte apoptosis, and expression of P53, Fas, Bax and Bcl-2 proteins in myocardium were determined in a rat model of acute myocardial infarction. Twenty-four male Sprague-Dawley rats weighing approximately 310 g were subjected to left coronary artery ligation. Seven days before surgery, the rats were randomized to receive cardiotrophin-1 (treated group) or phosphate-buffered saline (control group). Recombinant rat cardiotrophin-1 (2μg in 1 ml phosphate-buffered saline) or phosphate-buffered saline (1ml) was administered daily via the tail vein for 7 days (n=12 for each group). Hemodynamic parameters, apoptotic index, P53, Fas, Bax and Bcl-2 expression in myocardium were measured at 24 hours after coronary ligation. As compared with control animals, rats treated with cardiotrophin-1 had significantly higher mean arterial pressure, left ventricular systolic pressure and the maximum rate of left ventricular pressure rise or fall, and significantly lower left ventricular end-diastolic pressure. Cardiotrophin-1 pretreatment did not affect the heart rate, heart weight, body weight or the ratio of heart weight to body weight. The number of apoptotic cardiomyocytes in cardiotrophin-1 treated group was less than that in control group [(15.8±5.2) % vs (34.6±7.7) %, P<0.01]. Cardiotrophin-1 pretreatment significantly inhibited P53, Fas and Bax, and increased Bcl-2 expression in myocardium.

収録刊行物

参考文献 (24)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ